BIO
$264.49-0.51 (-0.19%)
Bio-Rad Laboratories, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The...
Recent News
Disappointing Results Hurt Bio-Rad Laboratories (BIO)
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf Partners Global Fund”. A copy of the letter can be downloaded here. The Fund returned 5.27% in the quarter, compared to the MSCI World’s 3.12 % and the MSCI World Value’s 3.34% return. The Fund returned 16.72% for the year, compared […]
Assessing Whether Bio-Rad Laboratories (BIO) Looks Undervalued After Recent Share Price Softness
Assessing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has attracted attention after a mixed stretch of returns, with the stock roughly flat over the past year but showing declines over the past month and past 3 months. See our latest analysis for Bio-Rad Laboratories. At the latest share price of $271.44, Bio-Rad’s short term share price momentum has been fading, while its 1 year total shareholder return of 9.56% contrasts with much weaker 3 and 5 year total...
International Markets and Bio-Rad (BIO): A Deep Dive for Investors
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […]
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.